News Releases
June 2, 2008: BiPar Sciences Presents Initial Clinical Data of BSI-201, a Novel DNA Repair Inhibitor
May 28, 2008: BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, with Phase 2 Trial in Uterine Cancer
May 15, 2008: BiPar Sciences Announces Clinical Data on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
May 8, 2008: BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
April 14, 2008: BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
April 10, 2008: BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
Feb. 14, 2008: BiPar names Hoyoung Huh, M.D., PH.D., President and Chief Executive Officer
Nov. 15, 2007: BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
Oct. 25, 2007: BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP1 Gene in Multiple Cancer Types
Oct. 24, 2007: BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity with BSI-401, its Second-Generation PARP Inhibitor
Oct. 22, 2007: BiPar Announces Upcoming Data Presentations Demonstrating Progress on PARP Inhibitor Drug Pipeline for Cancer
Sept. 25, 2007: BiPar Expands Management Team To Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials For Cancer
Sept. 19, 2007: BiPar Names G. Kirk Raab Acting Chief Executive Officer
May 17, 2007: BiPar Names John Schembri Chief Financial Officer
Feb. 26, 2007: BiPar Sciences Raises $35 Million to Advance Pipeline of Novel PARP Inhibitor Cancer Drug Candidates
Jan. 4, 2007: BiPar Sciences Begins Enrollment in Phase 1b Study of BSI-201
Aug. 7, 2006: BiPar Sciences Co-Founder Allan Basbaum Honored with Membership in Royal Society
June 14, 2006: BiPar Sciences Announces $5 Million Financing to Accelerate BSI-201 Clinical Program
June 7, 2006: BiPar Sciences to present at Pacific Growth Equities Life Science Growth Conference on June 14
March 7, 2006: Phase I Announcement
Dec. 20, 2004: BiPar Signs $13M in Series A Funding
Home > News & Events